Background: Accurate prediction of longitudinal changes in cognitive function would potentially allow for targeted intervention in those at greatest risk of cognitive decline. We sought to build a multivariate model using volumetric neuroimaging data alone to accurately predict cognitive function.
INTRODUCTION
Care for HIV-positive individuals has changed markedly over the past 3 decades. Successfully treated HIV infection is now the norm in Northern European settings, with more than 90% of patients receiving antiretroviral therapy in the United Kingdom of whom 90% have sustained suppression of plasma HIV RNA. 1 The rationale for universal treatment is clear after the publication of the INSIGHT START study. 2 As such, treatment of long-term comorbidities, such as cognitive impairment, is likely to make up a larger burden of care than opportunistic infections.
Cognitive impairment and accompanying neuroimaging abnormalities reportedly remain prevalent in the era of modern antiretrovirals. 3, 4 However, controlled data from exclusively virally suppressed patients suggest that the prevalence may be lower than previously described. 1, 5, 6 It is currently unclear whether virally suppressed patients experience further significant brain injury. Data from the Multicenter AIDS Cohort Study (MACS) and central nervous system HIV Anti-Retroviral Therapy Effects Research (CHARTER) cohorts suggest that most (.60%) HIV-positive individuals remain stable cognitively over time. 2, 7, 8 Approximately 10% experienced a decline in cognitive function, which was associated with ineffective antiretroviral therapy or treatment interruption. It should be noted that antiretroviral therapy was not universal in these cohorts, as effective suppression of plasma HIV RNA was only evident in 70% and 41%, respectively, which makes extrapolating these findings to successfully treated cohorts difficult.
Accurate prediction of cognitive impairment and longitudinal decline in cognitive function would be an important advance allowing for targeted investigation and treatment in those at the greatest risk of ongoing brain injury. The richness and availability of T1-weighted neuroimaging data makes it an ideal candidate for assessing HIV-associated brain injury.
Gray and white matter abnormalities have been reported in virally suppressed patients; however, the relationship between these findings and HIV-associated cognitive impairment is inconsistent. 3, 4, 6, 9 Therefore, it is unclear whether these changes have the specificity to discriminate between those with and without cognitive impairment with sufficient accuracy to be clinically useful.
These data have relied on the traditional approach of analyzing neuroimaging data, namely to derive biologically interpretable summary measures from regions of interest, which can then be analyzed with analysis of variance or its variants. To assess spatial relationships, a voxelwise "massunivariate approach" is commonly used. Although these approaches have been the building blocks of modern neuroscience, they have limitations. This mass-univariate approach tests a model at each voxel based on data across a group of subjects resulting in inferences that are valid at a group level. However, these findings have limited application for prediction at the individual level, thereby limiting their clinical impact. 10 A multivariate approach aims to do the reverse, namely use many voxels to predict a variable of interest. 11 This approach is particularly suited to neuroimaging data, given its inherent high dimensionality and multicollinearity, and has potentially greater sensitivity to detect subtle, spatially distributed patterns of anatomy, or activation allowing for prediction at an individual level. 10, 12 Multivariate techniques, such as machine learning models, broadly speaking can be used for classification or regression problems. The difference between them is whether the outcome variable to be predicted is discrete (classification) or continuous (regression). Supervised learning using labeled training data has yielded success in predicting cognitive impairment in other disease areas, 10 for example, allowing for the accurate classification of Alzheimer disease 13 and white matter injury after traumatic brain injury (TBI). 14 These multivariate approaches have barely been applied in HIV disease, but conceptually, there is no difference from other diseases. Zhang et al 15 used a multivariate classification model that was able to distinguish patients with HIVassociated neurocognitive dysfunction from HIV-negative individuals with mild cognitive impairment. In another study, Wade et al 16 distinguished HIV-positive individuals from HIV-negative controls using a random forest classifier. However, in both of these studies, viral suppression was not universal, which is likely to accentuate differences between HIV-positive and HIV-negative controls, therefore limiting the applicability of these findings to well-treated patients.
An alternative approach to building a model to predict a specific disease is to model how the aging process itself influences brain structure. Deviation of brain age predicted using neuroimaging data from chronological age, or brainpredicted age difference (brain-PAD), may result from neurodegeneration secondary to multiple insults that share a final common pathophysiological pathway of atrophy. Brain-PAD has recently been shown to be a potential biomarker of brain aging that relates to cognitive aging, physiological aging, and risk of death. 17 Using the same technique, accelerated aging has been reported after TBI, 18 whereas study of HIV-infected individuals has suggested premature but not accelerated brain aging. 19 However, this method has not been tested in other HIV-positive cohorts, and its ability to predict longitudinal cognitive function has not been determined.
Compared with prediction of cognitive impairment at baseline, the ability to be able to accurately predict longitudinal changes has the most clinical utility. Here, we sought to assess the prevalence of cognitive impairment and longitudinal decline in virally suppressed HIV-positive individuals. As a proof of principle, we aimed to build a generalizable, multivariate model using as inputs only T1-weighted magnetic resonance imaging (MRI) data and basic preprocessing to test 2 main hypotheses. First, that cognitive function could be predicted from volumetric T1-weighted MRI data, and second, confirm that brain-predicted age exceeded chronological age in virally suppressed HIV-positive individuals and this deviation would be associated with longitudinal decline in cognitive function.
METHODS

Participants
For these analyses, HIV-positive participants from the CHARTER cohort were included if they had plasma HIV RNA ,50 copies per milliliter at the time of baseline neuroimaging data (n = 139). The original CHARTER cohort and the neuroimaging substudy are described in more detail in Heaton et al 3 and Jernigan et al. 4 Longitudinal cognitive function data were collected approximately every 6 months and were available for most patients (n = 111 with 391 separate assessments of cognitive function, mean 3.5 visits). Comorbid conditions were classified as per Antinori et al 20 into "incidental" (eg, none or only mild TBI with no functional sequelae), "contributing" (eg, mild TBI with evidence of mild functional sequelae), and "confounding" comorbidities (eg, TBI without return to work/school).
Cognitive Function
All participants completed a comprehensive neuropsychological test battery testing the domains of attention, executive function, learning, recall, speed of information processing, motor function, and verbal fluency as previously described. 3 Demographically adjusted T-scores, where higher scores represent better cognitive function, were converted to deficit scores, and cognitive impairment was defined by a global deficit score (GDS) $0.5. 21 Longitudinal changes in cognitive function were defined using regression-based change scores using an independent normative sample (n = 296) as previously described. 8, 22 Briefly, this method calculates standardized z-scores for each test measure at each interval. These were then averaged to create a summary regression change score (sRCS), which was used to determine the longitudinal change status. The sRCS corresponding to the top 5% of the independent normative sample defined the improve status in this patient group, whereas the bottom 5% defined the decline status, with the remaining 90% defined as stable. For binary outcome analysis those labeled as stable or improve were combined as nondecliners.
Neuroimaging Acquisition and Preprocessing
T1-weighted MRI data were collected with General Electric 1.5T scanners at Johns Hopkins University (n = 30); Mt. Sinai School of Medicine (n = 25); University of California at San Diego (n = 47); University of Texas Medical Branch (n = 29); and the University of Washington (n = 8). Three dimensional T1-weighted images were acquired sagittally with spoiled gradient recall, time to recovery = 20 ms, time to echo = 6 ms, flip angle = 30°, field of view = 240 mm, 124 slices of 1.3 mm, and in-plane resolution 0.94 · 0.94 mm as previously described. 4 Three dimensional T1 images were preprocessed as described previously using SPM12 (University College London, United Kingdom). 6 Briefly, images were bias corrected, segmented into gray matter, white matter, and cerebrospinal fluid (CSF), and volumes calculated with the sum representing the total intracranial volume. Segmented images were then registered to a custom template, normalized to Montreal Neurological Institute (MNI) space using the DARTEL algorithm, 23 modulated to retain the volumetric characteristics of the original data and smoothed with a 6-mm full-width half-maximum kernel. To take advantage of the complementary data provided by gray and white matter, spatially normalized gray and white matter volumetric maps were spatially concatenated before multivariate analysis.
Multivariate Analysis
Supervised classification and regression was performed with the Pattern Recognition for Neuroimaging Toolbox (PRoNTo) 12 software package v.2.0 (Machine Learning and Neuroimaging Laboratory, University College London). For the purposes of classification, models were computed with support vector machines (SVMs) and Gaussian processes classification (GPC) for cognitive impairment defined using the GDS as previously described. To assess the ability of structural imaging data to predict cognitive function in a continuous nature, the global T-score was used as an outcome with Gaussian processes regression (GPR) and kernel ridge regression (KRR) models. Similarly, for longitudinal prediction, again using the processed baseline T1-weighted data as inputs, separate models were tested as before using longitudinal change status and sRCS as outcome variables.
Given the relatively small numbers in each group (n = 52 with cognitive impairment), predictive models were assessed using leave-one-out cross-validation. For classification, class (ie, cognitively impaired or not) accuracy and predictive value were calculated for each model. In addition, the area under the receiver operator curve (AUC) and the balanced accuracy (mean of class accuracies, important if groups are unbalanced) were calculated. This gives an estimation of the generalizability of the model to new data. For regression, model accuracy was quantified with the correlation (Pearson r), total variance explained (R 2 ), mean absolute error, and root mean squared error. P values were calculated using permutation testing with 1000 repetitions.
Predicting Brain Age Using a Normative Sample
An alternative multivariate approach was also used whereby each participant's apparent brain age was determined based on data from 2001 healthy subjects ranging from 18 to 90 years as previously described (see Supplemental Digital Content 1, http://links.lww.com/QAI/B149 for further details of data sources). 18, 19 The advantage of this model is that the training data were acquired across a range of different scanner hardware and acquisition protocols, therefore making this method potentially less prone to site/scanner related effects. This GPR model accurately predicted chronological age in the normative training set (r = 0.94, R 2 = 0.88, mean absolute error = 5.01 years). Brain-PAD, a measure of deviance from the normal aging trajectory was calculated as follows: brain-predicted agechronological age so that positive scores represented brains that appear "older" than expected.
Statistical Analysis
Univariate analyses were performed using x 2 , independent sample t-tests, Wilcoxon rank sum tests as appropriate, and in the case of comorbidity using analysis of variance with post hoc testing performed using Tukey honest significant difference. Relationships between cognitive domains and brain-PAD were determined with multiple linear regression covarying for age, comorbidity status, scanner, and total intracranial volume. Similarly, the relationship between brain-PAD and clinical variables was determined using multiple regression models with the same covariates. Both binary logistic regression and multiple linear regression were used to assess the relationship between longitudinal change status and sRCS with brain-PAD accounting for the same covariates. These analyses were performed using R v3.2.1, and P-values ,0.05 (2-tailed) were considered significant.
RESULTS
The baseline characteristics for the CHARTER participants (n = 139) are described in Table 1 . Potentially confounding medical problems were common, with 11.5% having "confounding" and 25.2% having "contributing" comorbidities. All participants had suppressed plasma HIV RNA but 2/121 (1.7%) had detectable CSF HIV RNA. Of these, one had CSF HIV RNA of 780 copies per milliliter and the other at the limit of detection at 50 copies per milliliter.
Cognitive Function
Using the GDS, cognitive impairment was present in 52 (37.4%) participants at the time of MRI scanning, which was more frequent in those with comorbidities [25/88 (28%) of those with "incidental" comorbidities, 14/35 [40%] with "contributing," and 13/16 [81%] with "confounding," x 2 2 = 16.3, P , 0.001]. However, only 6 (4.3%) met the criteria for HIVassociated dementia. Using regression-based change scores, 17 (14.5%) experienced cognitive decline, 83 (75.5%) remained stable, and 10 (9.1%) improved (Fig. 1) . There was no association between longitudinal cognitive outcome and comorbidity status (P = 0.21) nor cognitive impairment at baseline (P = 0.34).
Multivariate Prediction of Cognitive Function
Multivariate classification performance was not better than chance for both predicting baseline cognitive impairment nor patients who would experience longitudinal cognitive decline (Tables 2 and 3) . Selecting subjects at random from the nonimpaired or nondeclining groups to ensure balanced subject numbers for training and testing the models yielded similar results (AUC for cross-sectional SVM: 0.55 and GPC 0.57; and for longitudinal changes SVM: 0.41 and GPC 0.43).
Using a multiclass GPC to predict longitudinal change status (ie, stable, improve, or decline) also yielded poor results with a balanced accuracy of only 28.4% (P = 0.82) [decline: 70.6%, P = 0.94, positive predictive value (PPV) 13.2%; stable 14.5%, P = 0.31, PPV 63.2%; improve 0%, P = 1.00, PPV = 0%].
Both multivariate regression models predicted baseline global T-scores similarly well (KRR: r = 0.28, P = 0.02; GPR: r = 0.27, P = 0.001), with the KRR model explaining ;8% of the variance in global T-scores (Table 3) . A comparable linear model using total gray and white matter volumes did not predict global T-scores (model adjusted R 2 = 0.01, F 2,136 = 1.99, P = 0.14). Using KRR to predict longitudinal changes in cognitive function in a continuous manner (sRCS) was, however, unsuccessful (r = 20.07, P = 0.62, R 2 = 0.00, P = 0.66).
Multivariate Prediction of Brain Age
Using an alternative multivariate modeling approach, HIV-positive individual's brain-predicted age exceeded chronological age compared with the normative controls by mean (95% confidence intervals) 1.17 (20.14 to 2.53) years, P = 0.08. Both the patients with detectable CSF HIV RNA had an elevated brain-PAD: 7.1 and 7.0 years. Using multiple regression models, there was no association between brain-PAD and age nor duration of known HIV infection (P = 0.28 (Fig. 2 ). In addition, there was no relationship between current CD4 cell count and CD4:CD8 ratios n or hepatitis C status and brain-PAD (P = 0.56, P = 0.62 and P = 0.13, respectively). Those with prior AIDS had elevated brain-PAD In univariate analysis, increased brain-PAD was negatively correlated with executive function, motor function, and global T-scores with a negative trend for recall T-scores; however, after adjusting for potential confounders, these associations were no longer significant (see Supplemental Digital Content 2, http://links.lww.com/QAI/B149 for details) nor was there a relationship with cognitive impairment at baseline (P = 0.93). There was no association between brain-PAD and longitudinal changes in cognitive function (P = 0.52), nor with longitudinal change status (see Supplemental Digital Content 3, http://links.lww.com/QAI/ B149 for further details).
DISCUSSION
Here, we show that cognitive decline occurred in 15% of HIV-positive individuals with sustained suppression of plasma viremia. Although accurate discrimination between those with and without cognitive impairment was not possible using structural neuroimaging in this data set, a multivariate model could predict baseline cognitive function as a continuous measure, whereas an equivalent linear model could not. Successfully treated HIV-positive individuals also had older appearing brains than expected confirming previous work. This increase in apparent brain age was not associated with duration of HIV infection nor age, which suggests accentuated rather than accelerated aging. None of the multivariate models could predict longitudinal changes in cognitive function.
Multivariate machine learning analyses of HIV disease are sparse. Recently, Zhang et al 15 reported a multivariate classification model that distinguished HIV-associated neurocognitive dysfunction from mild cognitive impairment in HIV-negative individuals' longitudinal T1-weighted data. However, the number of patients with impairment in this study was small (n = 15) and only 80% had undetectable plasma HIV RNA. Using a random forest classifier on subcortical morphometry data, Wade et al 16 distinguished HIV-positive individuals from HIV-negative controls with an AUC of 0.72. However, only 38% of patients from this study had undetectable plasma viral loads, which is likely to accentuate differences from controls and again limits the applicability of these findings to well-treated patients.
One explanation for the inaccuracy of this work compared with the previous studies may be that all the participants here were on fully suppressive antiretroviral therapy, which may limit the extent of progressive HIVassociated brain injury. 24 Recent work from cohorts in North America 25 and Europe 26 has suggested that virally suppressed people living with HIV (PLWH) do not experience cerebral atrophy at an increased rate compared with HIV-negative controls despite evidence of reduced gray matter volume at study entry. Therefore, predicting HIV-associated longitudinal deteriorations in cognitive function on the basis of initial scans may be challenging. Furthermore, these data are consistent with our finding or stable cognitive function in most virally suppressed PLWH. The limited classification performance reported here may also be reflective of the models not being sufficiently accurate and the relatively small sample size. However, using a regression approach, cognitive function could be predicted with modest accuracy, and for binary classification, we used both SVM and GPC, which have been used successfully in other disease areas with comparable sample sizes. 10 One interpretation of these data is that in contrast to Alzheimer disease, HIV-associated cognitive impairment is generally mild in treated patients and not associated with sufficient brain volume reduction to enable accurate delineation between those with and without cognitive impairment. This is supported by only 4.3% meeting the criteria for HIV-associated dementia. A potential limitation is that only the GDS method of defining cognitive impairment was tested. Other, more specific methods of defining HIVassociated cognitive impairment may be more clearly associated with brain injury. Another limitation is the multiscanner nature of the data. This potentially increases variability unrelated to disease or cognitive function therefore limiting sensitivity and power. However, for a predictive neuroimaging model of cognitive impairment to be truly generalizable, it would need to maintain accuracy across a reasonable range of acquisition protocols, scanner vendors, and field strengths. As only 15% of well-treated patients experienced cognitive decline, accurate training of a classifier was not possible. Further study with a larger sample size studied over a longer time frame is necessary to determine whether predicting longitudinal cognitive decline in virally suppressed patients is possible. However, given the lack of any relationship between baseline volumetric data and longitudinal cognitive function, it is unlikely a larger sample that would result in a sufficiently accurate model to be useful, and other imaging modalities may be necessary to incorporate into the model.
The finding of older-appearing brains in HIV disease is in agreement with previous data with a similar, modest increase in apparent brain age. 19 This study also showed an association of brain-PAD with cognitive data, in contrast to the findings presented here. In this subset of the CHAR-TER cohort, the relationship between brain-PAD and cognitive function was confounded by comorbidity status. CHARTER recruited patients with minimal exclusions, whereas the COBRA study recruited participants without potentially confounding comorbidities, which may explain the differences in results. The finding of increased brain-PAD complements those of Horvath et al 27 who reported epigenetic changes suggestive of accelerated aging in both the blood and brain of HIV-infected individuals. However, in contrast to the conclusion of that study, we found no evidence of accelerated brain aging because age and duration of infection were not associated with increased brain-PAD. Also the modest increase in apparent brain age is less than that suggested by epigenetic changes. 27 In contrast to Horvath et al, 27 all the patients presented here had suppressed plasma HIV RNA that is likely to ameliorate ongoing HIV-associated brain injury. The cause of this accentuated or premature aging is not clear. It is likely to reflect brain injury from HIV replication in the central nervous system, which is supported by the association of greater brain-PAD in those with prior AIDS as well as the negative trend with nadir CD4 cell count-both suggestive of greater brain injury in those with longer duration of untreated infection. However, it should be noted that comorbidity status was clearly associated with brain-PAD, had a larger effect size than HIV-status (when compared with the normative control data set), and drove most of the associations with cognitive function given the attenuations of the associations after adjustment. This may reflect a final common pathway of pathology with many different types of neural insult converging in atrophy-mimicking the changes associated with age. These findings highlight the importance of accounting for comorbid conditions when it comes to correctly interpreting the etiology of cognitive and neuroimaging abnormalities in PLWH. If these conditions are not accounted for in either study design or analysis, the effect size of HIV may be overestimated. An important limitation is that this model was designed to detect the changes associated with healthy brain aging, and therefore, it may underestimate HIV-associated brain injury if it is distinct from the aging process. In addition, the lack of a study-specific control group makes the interpretation of measures "in years" less reliable despite the large normative sample used to train the model.
In conclusion, although superior to a comparable linear model, the performance of multivariate models to predict cognitive impairment and longitudinal cognitive decline fall well short of being clinically useful. Accounting for comorbidity is crucial when assessing brain injury in treated HIV disease, given the small proportion of virally suppressed HIVpositive individuals with severe cognitive impairment or who experience cognitive decline over time.
